CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

Table 1 Patient information and data involved in the study

Case	Age	Chemotherapy in Addition to Doxorubicin	Pathologic TNM	Stage	Ki67	RCB Score	RCB Class	CREB3L1 IRS
1	40-49	Cytoxan, Taxol, Xeloda	ypT2pN3M1	IV	84	4.186	3	1
2	50-59	Cytoxan, Xeloda, Taxol	ypT2pN1M1	IV	45	4.387	3	0.5
3	50-59	Cytoxan, Taxol	ypT1bN0M0	IA	90	1.340	1	0.5
4	30-39	Cytoxan, Taxol	ypT2N3M0	IIIC	70	4.340	3	1
5	40-49	Cytoxan, Taxol	ypT0N1miM0	IB	95	1.125	1	10
6	50-59	Halaven, Paraplatin, Taxol	ypT2N1M1	IV	90	3.290	3	0.5
7	50-59	Cytoxan, Paraplatin, Taxol	ypT1cN1M0	IIA	30	3.014	2	6
8	40-49	Cytoxan, Taxol	ypT0N0M0	0	95	0	0	8
9	40-49	Cytoxan, Paraplatin, Taxol, Xeloda	ypT2N1M1	IV	35	1.390	2	2
10	40-49	Cytoxan, Gemzar, Paraplatin, Taxol	ypT1bN1M0	IIA	20	3.023	2	8
11	40-49	Cytoxan, Taxol	ypT2N0M0	0	60	0	0	2
12^a	50-59	Arimidex, Cytoxan, Paraplatin, Taxol	ypT2N1M0	IIB	80	3.900	3	0
13	40-49	Cytoxan, Taxol, Xeloda	ypT2N0M0	0	85	2.452	2	1
14	70-79	Cytoxan, Taxol	ypT0N0M0	0	90	0	0	6
15	50-59	Cytoxan, Taxol	ypT1miN0M0	0	95	1.322	1	6
16^a	50-59	Arimidex, Cytoxan, Taxol	ypT1cN0M0	IA	95	2.009	2	4
17^a	40-49	Arimidex, Cytoxan, Taxol	ypT1cN0M0	IA	70	2.140	2	1
18^a	60-69	Arimidex, Cytoxan, Taxol	ypTisN0M0	0	80	0	0	8

All patients were diagnosed and treated between 2011 and 2017 at UT Southwestern University Hospitals. Patient age range and chemotherapeutic drugs in addition to doxorubicin used in the treatment are shown. Response of the tumors to the chemotherapy measured through RCB Scores and RCB Classes, CREB3L1 expression in the tumors measured by IRS values, percentage of tumor cells positively stained by anti-Ki67, and other clinical characterization of the tumors is also presented
^aThese patients had two different breast cancers: one breast with TNBC; the other with ER positive cancer. Only TNBC but not the ER-positive tumors were analyzed in this study

ISSN: 1471-2407